Sign up for news & promotions:
MET Primary Antibody
|Aliases||HGFR; AUTS9; RCCP2; c-Met; DFNB97|
|Formulation||Purified antibody in PBS with 0.05% sodium azide|
|Immunogen||Purified recombinant fragment of human MET (AA: 743-932) expressed in E. Coli.|
|Shipping Information||This product will ship in a box containing blue ice at a temperature of 4°C. Learn More|
|ICC (Immunocytochemistry)||1/100 - 1/500|
|FCM (Flow Cytometry)||1/200 - 1/400|
|WB (Western Blot)||1/500 - 1/2000|
Figure 1: Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)
Figure 2:Western blot analysis using MET mAb against human MET (AA: 743-932) recombinant protein. (Expected MW is 47 kDa)
Figure 3:Western blot analysis using MET mAb against HEK293 (1) and MET (AA: 743-932)-hIgGFc transfected HEK293 (2) cell lysate.
Figure 4:Immunofluorescence analysis of Hela cells using MET mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)
Figure 5:Flow cytometric analysis of MCF-7 cells using MET mouse mAb (green) and negative control (red).
|Description||This gene encodes a member of the receptor tyrosine kinase family of proteins and the product of the proto-oncogene MET. The encoded preproprotein is proteolytically processed to generate alpha and beta subunits that are linked via disulfide bonds to form the mature receptor. Further processing of the beta subunit results in the formation of the M10 peptide, which has been shown to reduce lung fibrosis. Binding of its ligand, hepatocyte growth factor, induces dimerization and activation of the receptor, which plays a role in cellular survival, embryogenesis, and cellular migration and invasion. Mutations in this gene are associated with papillary renal cell carcinoma, hepatocellular carcinoma, and various head and neck cancers. Amplification and overexpression of this gene are also associated with multiple human cancers.
|References (references)||1.Oncotarget. 2015 Jun 30;6(18):16215-26.
2.Br J Cancer. 2015 Feb 3;112(3):429-37.